Introduction
Advances in hematopoietic cell transplantation (HCT) and supportive care have led to substantial improvements in transplant outcomes and an increased number of long-term HCT survivors [ 1 ]. Transplant survivors are at considerable risk for developing significant late effects and experience mortality rates higher than the general population [ 2 , 3 ]. One challenge faced in the post-HCT setting is the development of metabolic syndrome (MetS), with reported prevalence rates of 31–49% [ 4 – 8 ]. HCT recipients are predisposed to develop MetS through several mechanisms, including conditioning regimen-mediated damage to the neurohormonal system and vascular endothelium, as well as the immunological and inflammatory effects of allografting (including subsequent graft-versus-host disease (GVHD) and its therapy) [ 4 ]. Individuals in the general population with MetS are twice as likely to develop cardiovascular disease than those without MetS [ 9 ]. A better understanding of MetS following HCT may prove to be significant, as HCT survivors are known to be at increased risk for cardiovascular morbidity and mortality. In the Bone Marrow Transplant Survivor Study (BMTSS), the risk of premature cardiovascular-related death following HCT was found to be increased 2.3-fold compared to the general population [ 2 , 3 ]. Similarly, others have reported the risk of cardiovascular hospitalizations and mortality to be increased by 3.6-fold in HCT recipients compared to the general popuation [ 10 ].
Intensive chemotherapy and radiation have been associated with MetS and contribute to the development of this syndrome post-HCT, especially in heavily pre-treated populations [ 11 , 12 ]. MetS has not yet been proven to impact cardiovascular risk after HCT. However, an understanding of the incidence and risk factors for MetS and cardiovascular disease following HCT provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. Therefore, a collaboration was established between the Center for International Blood and Marrow Transplant Research (CIBMTR) Late Effects and Quality of Life Working Committee and the European Group for Blood and Marrow Transplantation (EBMT) Complications and Quality of Life Working Party with the goal to review literature, including previously published guidelines for screening and preventive practices for HCT survivors [ 13 – 15 ]. We subsequently provide specific screening and preventive practice recommendations for MetS and cardiovascular disease appropriate to HCT recipients based on published evidence and expert opinion.
Metabolic syndrome
MetS is a cluster of interrelated factors that increases the risk of cardiovascular disease, diabetes mellitus (DM), and all cause mortality [ 16 – 18 ]. The International Diabetes Foundation (IDF) estimates that 25% of the world’s adult population has MetS [ 19 ]. The four core clinical measures are increased body weight/visceral adiposity, elevated lipids, raised blood pressure (BP), and hyperglycemia/insulin resistance (IR) [ 20 ]. The individual diagnostic criteria of MetS have varied over time according to the different definitions applied. The diagnostic criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) [ 9 , 21 ], the IDF and the American Heart Association (AHA) [ 17 ] and the World Health Organization (WHO) [ 22 ] are shown in Table 1 . A comparison of various definitions in terms of their predictive value established that the prevalence of MetS was significantly greater when using the criteria of the AHA and IDF compared with the NCEP ATPIII definition [ 23 ]. However, the risks of cardiovascular events and death were markedly greater for participants who satisfied any of the criteria for diagnosis of MetS compared with healthy individuals. This supports other reports that found agreement between MetS components and cardiovascular risk factors in the general population [ 24 , 25 ].
1. Abdominal obesity
Obesity, defined as a body mass index (BMI) ≥30 kg/m 2 , affects 35% of adults in the United States [ 26 ] and 10–30% of adults in Europe [ 27 ]. Obese persons have a higher risk of developing serious medical conditions, including hypertension (HTN), dyslipidemia, type 2 DM, coronary heart disease (CHD), and ischemic stroke, and have a higher mortality than the non-obese population [ 28 ]. However, BMI is an insufficient measure of abdominal obesity. Waist circumference, which emphasizes visceral adipose deposits, is preferentially used in the evaluation of abdominal obesity when defining MetS (see Table 1 ) as this distribution of fat accumulation independently confers cardiometabolic risk [ 29 , 30 ]. Yet, as studies reporting waist circumference at the time of and following HCT are limited, BMI may act as a possible surrogate.
BMI ≥35 kg/m 2 (severely obese) is part of the HCT-specific Comorbidity Index since 2005, as this was determined to be a risk factor for increased non-relapse mortality (NRM) [ 31 – 34 ]. While pre-transplant obesity can influence body composition following HCT, changes in waist circumference can be seen independent of pre-existing obesity. Despite what may be a normal BMI, HCT survivors are at an increased risk to develop sarcopenic obesity (increase in percent fat mass, decrease in lean body mass), which can significantly contribute to IR [ 35 , 36 ]. A longitudinal study using dual X-ray absorptiometry (DXA) to calculate body fat mass index (BFMI) in 82 patients found the prevalence of a high BFMI was greater at 2–3 years following allo-HCT than in healthy controls [ 37 ]. Corticosteroids, which remain the first line treatment of GVHD, contribute to sarcopenic obesity by promoting muscle atrophy and may contribute to obesity in the early post-HCT period [ 5 , 38 ]. Robust data on the changes in abdominal obesity following autologous HCT (auto-HCT) are lacking. One study evaluated metabolic and body composition changes in 32 patients with multiple myeloma who had received three lines of intensive treatment, including at least one HCT. At a median duration of 6 years from diagnosis, DXA identified sarcopenic obesity in 65% of patients [ 39 ]. Importantly, the development of sarcopenic obesity following HCT has yet to be independently associated with increased cardiovascular mortality. In the pediatric population, a cross-sectional study evaluating 54 allo-HCT survivors and 894 healthy participants found a deficiency in lean mass (as identified by DXA) as compared to fat mass in HCT survivors [ 40 ]. A prospective, descriptive, cross-sectional study evaluating children and adolescents for the development of MetS post-HCT found that 73% of individuals with this diagnosis had a characteristic of abdominal obesity (abdominal circumference >75 th percentile by age and gender) [ 5 ].
Screening and preventive recommendations
The United States Preventive Services Task Force (USPSTF) and the National Heart, Lung, Blood Institute (NHLBI) recommend screening for obesity in all adults and children >2 years of age, though no recommendation is made regarding appropriate intervals for screening. Current guidelines for HCT recipients do not provide specific screening recommendations for abdominal obesity, though education and counseling regarding regular exercise, healthy weight, and dietary counseling are encouraged [ 14 , 15 ]. Given the increase in abdominal obesity that can occur after HCT, clinicians should consider monitoring body composition at each visit, with regular measurement of height, weight, and waist circumference (at least yearly). Based on what is known in other populations, we recommend that patients with a BMI ≥30 kg/m 2 , waist circumference >102 cm (>40 inches) in men or >88 cm (>35 inches) in women, or significant increases in either of these measurements should be considered for intensive, multicomponent behavioral interventions. DXA may be used to assist evaluation and monitoring of changes in body composition in survivors of HCT.
2. Dyslipidemia
Dyslipidemia, defined as elevated levels of total cholesterol, low-density lipoprotein (LDL) cholesterol or triglycerides, or low levels of high-density lipoprotein (HDL) cholesterol, is an important risk factor for CHD and ischemic stroke [ 41 , 42 ]. The prevalence of dyslipidemia is high in the general population: in 2000, approximately 25% of adults in the United States had total cholesterol greater than ≥240 mg/dL (≥6.2 mmol/L) or were taking lipid-lowering medication [ 43 ]. A high prevalence of dyslipidemia has also been reported in European countries [ 44 , 45 ]. Of the various dyslipidemias, low HDL (<40–50 mg/dL, <1.0–1.3 mmol/L) and hypertriglyceridemia (>150 mg/dL, >1.7 mmol/L) have been incorporated into the diagnostic criteria of MetS (see Table 1 ).
Survivors of allo-HCT are at an increased risk of post-transplant dyslipidemia. In a retrospective cohort study comparing incidence and risk factors for cardiovascular events, allo-HCT recipients had significantly higher risk of new-onset dyslipidemia (RR: 2.31; 95% CI, 1.15 to 4.65) compared to auto-HCT recipients [ 46 ]. Single institution studies have estimated the incidence of hypercholesterolemia and/or hypertriglyceridemia following allo-HCT to be 43–73% [ 47 , 48 ]. The onset of dyslipidemia post-HCT can be rapid, with the median interval to development of hypertriglyceridemia and hypercholesterolemia being 8 and 11 months following allo-HCT, respectively, in one single center experience [ 47 ]. Factors predicting development of post-HCT dyslipidemia include family history of hyperlipidemia, obesity, high-dose total body irradiation (TBI), grade II-IV acute GVHD, chronic GVHD, and chronic liver disease [ 5 , 8 , 47 – 49 ]. In addition, immunosuppressant medications (e.g., sirolimus, calcineurin inhibitors, corticosteroids) not only increase lipid levels but also lead to significant drug-drug interactions with 3-hydroxy-3-methyl-gutaryl (HMG)-CoA reductase inhibitors (statins) via the cytochrome p450 pathway [ 50 , 51 ]. Data regarding the incidence of dyslipidemia following auto-HCT are limited. In a single center analysis evaluating late post-HCT cardiovascular complications in 1379 patients, which included both auto- and allo-HCT recipients, 1-year post-HCT dyslipidemia requiring treatment was associated with an increased risk for stroke (HR 7.4; 95% CI, 1.2–47) [ 52 ]. In the pediatric population, the risk of hypercholesterolemia is high in childhood cancer survivors who underwent auto-HCT (HR = 3.2; CI 1.7–5.9) [ 53 ].
Screening and preventive recommendations
The USPSTF strongly recommends screening for lipid disorders every 5 years in men ≥35 years, women ≥45 years, and persons ≥20 years at increased risk for CHD, while the NHLBI recommends screening in children between the ages of 9–11 years or earlier in those with family history. Current guidelines for HCT recipients recommend similar screening practice for dyslipidemia amongst the general population [ 14 , 15 ]. We recommend standard-risk patients (including auto-HCT recipients without personal risk factors) should follow these guidelines. However, early onset of dyslipidemia following allo-HCT is not uncommon, especially in high-risk patients. Thus, we propose early assessment of exposures and risk factors in all HCT patients. For recipients of allo-HCT, we suggest an initial lipid profile 3 months after HCT. For high-risk patients with ongoing risk factors (including those on sirolimus, calcineurin inhibitors, corticosteroids), we suggest repeat evaluation every 3–6 months. In recipients without ongoing risk factors, we suggest repeat evaluation according recommendations for the general population. Non-pharmacologic management of dyslipidemia primarily involves lifestyle modifications such as diet (low saturated fat and low cholesterol), exercise (or other regular physical activities), weight reduction, smoking cessation, and limiting alcohol intake. Although not validated amongst HCT survivors, we recommend use of the Framingham risk score ( http://cvdrisk.nhlbi.nih.gov ) to assess cardiovascular risk and guide therapy decisions [ 41 ]. The safety of lipid-lowering agents must be considered in the pediatric population, as the AHA recommends considering drug therapy for high-risk lipid abnormalities in boys ≥10 years of age and after onset of menses in girls, preferably after a 6 to 12 month trial of saturated fat- and cholesterol-restricted dietary management [ 54 ].
3. Hypertension
HTN, defined as a systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, is a worldwide epidemic affecting approximately ~25% of adults [ 55 ]. Of note, the blood pressure criteria used in most definitions of MetS is systolic BP ≥135 mmHg or diastolic BP ≥85 mmHg (or drug treatment for HTN) (see Table 1 ), which is classified as pre-hypertension according to the report from the Eighth Joint National Committee (JNC 8) [ 56 ].
An analysis of the BMTSS showed that after adjustment for age, sex, race, and BMI, allo-HCT recipient were 2.06 times (95% CI, 1.39–3.04) more likely to report HTN as compared to sibling donors or auto-HCT recipients, who had a similar risk (OR, 0.96; 95% CI, 0.65–1.44) [ 57 ]. Similarly, a retrospective, single-institution evaluation of 265 long-term transplant survivors reported that allo-HCT recipients have an increased risk of HTN (RR: 2.50; 95% CI, 1.19 to 5.27) compared to auto-HCT patients [ 46 ]. A direct cause and effect relationship of conditioning regimen, acute or chronic GVHD and HTN was not established [ 57 ]. Two large retrospective studies did not show a significant difference in the incidence of HTN in allo-HCT recipients with or without GVHD [ 57 , 58 ]. It appears that HTN is related to use of certain GVHD therapies (e.g., calcineurin inhibitors, steroids) rather than GVHD induced pro-inflammatory cytokine response and endothelial damage. Although pediatric patients are less likely than adults to have pre-transplant HTN as well as any risk factors for HTN, an analysis of 1-year survivors of allo-HCT found a similar incidence of post-HCT HTN in adult (68%) and pediatric (73%) HCT survivors [ 59 ]. In multivariate analyses, exposure to cyclosporine increased the risk of HTN post-HCT (RR: 1.6; 95% CI, 1.1–2.5), but only within the first 2 years, suggesting this may revert once medications are stopped.
Screening and preventive recommendations
The USPSTF recommends BP assessment every 3 to 5 years in adults aged 18–39 years with normal BP (<130/85 mm Hg) who do not have other risk factors and annually in adults aged ≥40 years and for those who are at increased risk for high BP. In children, the NHLBI recommends BP assessment yearly after the age of 3 years, interpreted for age, sex, and height. Current guidelines for HCT recipients recommend at least annual BP assessment in children and BP assessment every other year in adults [ 14 , 15 ]. We recommend BP assessment for HCT recipients at every clinic visit (at least yearly). The JNC 8 report recommends initiating pharmacologic treatment for BP of ≥150/≥90 mmHg in persons ≥60 years of age (to a BP goal of <150/<90 mmHg) and for BP of ≥140/≥90 in persons 30–59 years of age (to a BP goal of <140/<90) [ 56 ]. In the absence of HCT-specific evidence, these goals can be used to guide management of HCT recipients, but other factors such as end organ compromise (cardiac or renal failure) and therapy with calcineurin inhibitors also need to be taken into account.
4. Insulin resistance/diabetes mellitus
DM, which affects almost 10% of the adult population worldwide, is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of DM is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. The American Diabetes Association (ADA) defines DM as a fasting plasma glucose ≥126 mg/dl (≥7 mmol/L), a hemoglobin A1C (HbA1C) ≥6.5%, a 2–hour plasma glucose ≥200 mg/dl (≥11.1 mmol/L) during an oral glucose tolerance test, or a random glucose ≥200 mg/dl (≥11.1 mmol/L) in a patient with classic symptoms or hyperglycemia or hyperglycemic crisis [ 60 ]. Impaired fasting glucose (IFG, fasting glucose 100–126 mg/dL (5.6–7 mmol/L)) or DM are used in most definitions of MetS ( Table 1 ). The treatment of DM may reduce the progression of microvascular and cardiovascular disease [ 61 – 64 ]. Although randomized trials have failed to demonstrate an unequivocal benefit, the identification of patients by screening allows for earlier intervention with potential reduction in complications [ 65 , 66 ].
While hyperglycemia and impaired glucose tolerance (IGT) are well-recognized complications of cancer and GVHD treatment (corticosteroids), data regarding the long-term risk of DM in HCT survivors are limited [ 67 ]. In the BMTSS, both allo-HCT (OR, 3.65; 95% CI, 1.82–7.32) and auto-HCT (OR: 2.03; 95% CI, 0.98–4.21) recipients were more likely to report DM than sibling donors [ 57 ]. The incidence of post-HCT DM was 30% among 1-year allo-HCT recipients in both adult and pediatric populations [ 59 ]. In this study, exposure to high-dose corticosteroids (cumulative prednisone dose of > 0.25 mg/kg/day) increased the likelihood of developing DM (RR, 3.6; 95% CI, 1.7–7.5) and for having persistent DM at 2 years post-HCT (RR, 4.1; 95% CI, 1.0–18.2). While data regarding the incidence of IR in survivors of adult HCT are lacking, the incidence of IR for pediatric HCT survivors has been estimated to be 10–52% in single center studies [ 68 – 71 ]. These reports suggest an increased risk for IR/DM in survivors of both allo- and auto-HCT compared to patients treated with chemotherapy alone or untreated siblings, even when off immunosuppressive treatments. Preliminary data from a cross sectional study including 151 HCT survivors (76.8% allo-HCT) and 92 sibling controls found HCT survivors who had received TBI conditioning to be significantly more likely to have IR than their sibling controls, but there was no increased risk of IR for those patients who had a history of acute or chronic GVHD (personal communication, Baker KS). Multiple studies found high-dose TBI as a risk factor for IR and IGT, in addition to older age and lipodystropic body type [ 70 – 73 ]. While data have not demonstrated an increased risk of diabetes to be directly associated with history of GVHD, further study is warranted.
Screening and preventive recommendations
The most common tests to screen for diabetes are fasting plasma glucose, two-hour plasma glucose during an oral glucose tolerance test, and HbA1C. The USPSTF recommends screening for abnormal blood glucose (HbA1C, fasting plasma glucose or oral glucose tolerance test (OGTT)) every 3 years in adults aged 40–70 years who are overweight or obese. The NHLBI recommends screening with a fasting glucose every 2 years after the age of 10 years in overweight children with other risk factors. Current guidelines for HCT recipients recommend screening for type 2 DM every 3 years in adults aged ≥45 years or in those with sustained higher BP (>135/80 mm Hg) and fasting glucose at least every 5 years pediatric survivors [ 14 , 15 ], which should be appropriate for standard-risk patients. For high-risk patients with ongoing risk factors (including those on systemic corticosteroids), we recommend screening for abnormal blood glucose (HbA1C or fasting plasma glucose) 3 months after HCT with repeat evaluation every 3–6 months. For patients with IFG, we encourage weight reduction and increased physical activity while patients with type 2 DM should implement lifestyle therapy and pharmacotherapy, if necessary, to achieve near-normal HbA1C (<7%).
5. Coronary heart disease
More people die from cardiovascular disease each year than from any other cause. Cardiovascular disease is caused by disorders of blood vessels and is closely related to atherosclerosis, where endothelial lesions occur up to decades before clinical manifestations [ 74 , 75 ]. Risk factors for arteriosclerosis in the general population are well established and include smoking, arterial HTN, obesity, DM, dyslipidemia, familial history of CHD, physical inactivity, male gender and elevated C-reactive protein [ 76 ].
Several studies have attempted to assess the incidence of cardiovascular disease after HCT, with or without a comparison to a control population. A retrospective multicenter EBMT analysis showed that 3.6% of long-term allo-HCT survivors transplanted between 1990 and 1995 had a cardiovascular event in at least one arterial territory observed [ 77 ]. The cumulative incidence of a first cardiovascular event 15 years after HCT was 6% (95% CI, 3%-10%). One study reported a cumulative incidence of 7.5% for the first cardiovascular event at 15 years post allo-HCT, as compared with 2.3% post auto-HCT [ 46 ]. In multivariate analysis, allo-HCT, in addition to at least 2 of 4 cardiovascular risk factors (HTN, dyslipidemia, DM, and obesity) was associated with a higher incidence of cardiovascular events (RR: 12.4; P=.02). In a retrospective cohort study, ≥2-year HCT survivors experienced an increased incidence of cardiovascular death (adjusted incidence rate difference, 3.6 per 1000 person-years (95% CI, 1.7 to 5.5) when compared with the general population [ 10 ]. In this study, an increased cumulative incidence was also found for ischemic heart disease, cardiomyopathy or heart failure, stroke, vascular diseases, and rhythm disorders and an increased incidence of related conditions that predispose toward more serious cardiovascular disease (HTN, renal disease, dyslipidemia, and DM). In another study, HCT recipients had significantly higher rates of cardiomyopathy (4.0% vs. 2.6%), stroke (4.8% vs. 3.3%), dyslipidemia (33.9% vs. 22.3%) and DM (14.3% vs. 11.7%) (P<.05 for all comparisons) than the general population, though lower rates of ischemic heart disease (6.1% vs. 8.9%; P<.01) [ 49 ]. In the BMTSS, survivors of both allo- and auto-HCT were not more likely to report arterial disease, myocardial infarction or stroke than sibling donors [ 57 ]. One series, which included 42.7% allo-HCT recipients, reported an incremental increase in 10-year incidence of cardiovascular disease by number of cardiovascular risk factors (4.7% (no factor), 7.0% (one risk factor), 11.2% (≥2 risk factors), P<.01); the risk was especially high (15.0%) in patients with multiple risk factors and pre-HCT exposure to anthracyclines or chest radiation [ 78 ]. In the adult population, it is important to acknowledge that an increasing number of older patients are undergoing allo-HCT with reduced intensity conditioning and that future studies are needed to assess the incidence of cardiovascular complications in this population.
In children with acute lymphoblastic leukemia, high-dose TBI and cranial irradiation correlated with multiple adverse cardiovascular factors including central adiposity, HTN, IR and dyslipidemia [ 79 , 80 ]. Some studies have analyzed the correlation with GVHD and either found a correlation [ 81 ] or not [ 46 , 57 ] and if so, more likely with acute than chronic GVHD [ 77 , 78 ].
Screening and preventive recommendations
In the general population, a person's 10-year risk for CHD is determined based on age, gender, and conventional CHD risk factors such as smoking, HTN, and dyslipidemia (Framingham risk score, http://cvdrisk.nhlbi.nih.gov )) [ 82 ]. Overall, the benefits of screening with resting or exercise electrocardiography (ECG) or for non-traditional risk factors, including coronary artery calcification on electron-beam computerized tomography (EBCT), have not been clearly demonstrated to outweigh harms. The USPSTF recommends against screening with ECG in asymptomatic adults with low risk for CHD and concludes that there is insufficient evidence to assess the balance of benefits and harms of screening with resting or exercise ECG in asymptomatic adults at intermediate- or high-risk for CHD events. Similarly, the USPSTF finds insufficient evidence to assess the balance of benefits and harms of using non-traditional risk factors to screen asymptomatic men and women with no history of CHD to prevent CHD events. Current guidelines for HCT recipients do not provide specific screening recommendations for coronary heart disease [ 14 ]. Decisions about screening in adults at increased risk should be made on a case-by-case basis and after careful discussion with the patient about the risks and benefits of screening. Although little data are available about specific interventions in the HCT populations, we recommend a similar approach.
6. Ischemic Stroke
Stroke is the fourth leading cause of death in the United States, whereas globally it is the second most common cause of mortality and the third most common cause of disability [ 83 , 84 ]. Globally, stroke incidence from ischemia is 68% and 32% from hemorrhagic stroke (intracerebral and subarachnoid combined) [ 85 ]. Pediatric stroke is a top ten cause of death in children, occurring at 11 per 100,000 children per year, with acute ischemic stroke accounting for half of all cases [ 86 – 88 ].
The cumulative incidence of stroke after adult HCT has been reported in single center series to be 1–5% at a median of 4–10 years following HCT [ 10 , 46 , 49 , 79 , 89 ]. In one study of 3833 HCT survivors of ≥1 year (71.3% allo-HCT), the prevalence of stroke at a median of 10.8 years since HCT was slightly higher than in a matched general population sample (4.8% vs 3.3%) [ 49 ]. Reported risk factors for stroke include hyperlipidemia, suboptimal physical activity, HTN treatment before HCT, BMI ≥ 30 kg/m 2 at HCT, and recurrence of the original disease [ 10 , 49 , 52 ]. The risk of stroke did not differ statistically between auto- or allo-HCT, gender, age at HCT, TBI dose, smoking history, donor type, stem cell source, fruit or vegetable intake, and prior cranial radiation [ 10 , 49 , 52 , 57 ]. A history of chronic GVHD was associated with an increased risk of stroke among ≥5-year HCT survivors (OR, 2.0; 95% CI, 1.1–3.6) in one study [ 49 ], while it was not statistically associated with risk of stroke in the other studies. Although ischemic stroke is an indication for HCT in sickle cell disease (SCD), reports indicate that there is no increased risk post-HCT in this population. In one report of pediatric SCD patients, 2 had TIAs after allo-HCT but not stroke [ 90 ]. Similarly, another study of pediatric SCD matched related allo-HCT patients did not report stroke in those with successful engraftment [ 91 ]. Adult SCD may have a higher risk of stroke and allo-HCT studies in the adult population are ongoing.
While the reported incidence of stroke in HCT survivors is low, it may be under recognized due to under reporting. Central nervous system complications – such as stroke, posterior reversible encephalopathy syndrome (PRES) and seizures - also occur frequently in the early post-HCT follow-up with significant impact on patient survival [ 92 ]. Beside the well-known PRES, calcineurin inhibitors may cause a reversible cerebral vasoconstriction syndrome that can progress to cerebral infarction [ 93 ]. Furthermore neurovascular complication – including stroke and transient ischemic attacks (TIA) – occur commonly upon initial presentation of thrombotic microangiopathies presentation and cryptogenic stroke may develop before the onset of alarming hematologic abnormalities [ 94 , 95 ].
Screening and preventive recommendations
The risk of a first stroke can be assessed by a global risk assessment tool such as the American Heart Association/American College of Cardiology Cardiovascular Risk Calculation online tool for adults ( http://my.americanheart.org/cvriskcalculator ), which has also been endorsed by the American Academy of Neurology [ 96 ]. The USPSTF recommends against screening for asymptomatic carotid artery stenosis in the general adult population. Preventive practice includes performing moderate to vigorous aerobic physical activity for at least 40 minutes 3–4 times a week, statin therapy according to 10 year calculated cardiovascular risk, implementation of a Mediterranean diet, HTN therapy, and weight loss in overweight and obese patients. Current guidelines for HCT recipients do not provide specific screening recommendations for stroke [ 14 ]. In the absence of HCT-specific evidence, these goals represent appropriate guidelines for HCT recipients.
Recommendations for screening and preventive practices
While evidence demonstrating the benefits of screening and preventive practices in HCT survivors is lacking, this review of MetS and cardiovascular disease emphasizes the high incidence of cardiovascular risk factors and the related morbidity and mortality experienced by HCT recipients. Based on this data, we present published guidelines for general population and HCT survivors ( Tables 2 and 3 ) as well as our consensus recommendations on the screening and preventive practices ( Table 4 ) for MetS and cardiovascular disease. We also present risk factors to consider when screening for components of metabolic syndrome in transplant recipients ( Table 5 ). HCT survivors with no identifiable risk factors should be counseled to have a healthy lifestyle and to follow the well-established screening recommendations for the healthy population. However, high-risk patients with ongoing risk factors should be more closely monitored.
Although not addressed formally in this manuscript, endocrine abnormalities, such as male hypogonadism, premature menopause, and hypothyroidism can occur following HCT and may contribute to MetS cardiovascular risk. Health care providers should be aware of these risks and evaluate for these conditions in HCT survivors, especially in the presence of MetS or those with risk factors.
A number of online tools are available to help providers assess risk in patients. In addition to the Framingham risk score ( http://cvdrisk.nhlbi.nih.gov ), the AHA released a mobile application in 2013 ( http://tools.acc.org/ASCVD-Risk-Estimator ) to estimate 10-year and lifetime risks for atherosclerotic cardiovascular disease in healthy subjects considering age, ethnicity, gender, systolic BP, history of smoking and DM, total and HDL cholesterol. However, these calculators were designed for the general population and have limitation by age, ethnicity, and/or comorbid conditions. Furthermore, it is important to acknowledge that these tools have not been validated in HCT survivors and thus potentially underestimate risk in this population.
Conclusion
We provide a consensus recommendations for screening and preventive measures for MetS and cardiovascular disease in recipients of HCT. Such effort by the CIBMTR and EBMT Late Effects Working Groups is intended to raise awareness of the cardiovascular risk in HCT survivors and lead to practices that will decrease related mortality. This document does not discuss strategies to achieve these practices (e.g. survivorship clinics, rehabilitation or exercise programs) given the differences in health care environments between different countries, but efforts to facilitate such strategies to be developed at the local or national level are needed.
Supplementary Material
Financial Disclosure: The authors have no financial interests to disclose.
Conflict of Interest
The authors declare no conflict of interest.
References
1 Majhail NS Tao L Bredeson C Davies S Dehn J Gajewski JL Prevalence of hematopoietic cell transplant survivors in the United States Biol Blood Marrow Transplant 2013 19 10 1498 1501 23906634 10.1016/j.bbmt.2013.07.020 PMC3779514
2 Bhatia S Francisco L Carter A Sun CL Baker KS Gurney JG Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study Blood 2007 110 10 3784 3792 17671231 10.1182/blood-2007-03-082933 PMC2077324
3 Bhatia S Robison LL Francisco L Carter A Liu Y Grant M Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study Blood 2005 105 11 4215 4222 15701723 10.1182/blood-2005-01-0035 PMC1895040
4 Majhail NS Flowers ME Ness KK Jagasia M Carpenter PA Arora M High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation Bone Marrow Transplant 2009 43 1 49 54 18724397 10.1038/bmt.2008.263 PMC2628412
5 Paris C Yates L Lama P Zepeda AJ Gutierrez D Palma J Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents Pediatr Blood Cancer 2012 59 2 306 310 22302361 10.1002/pbc.24104
6 Annaloro C Usardi P Airaghi L Giunta V Forti S Orsatti A Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation Bone Marrow Transplant 2008 41 9 797 804 18195686 10.1038/sj.bmt.1705972
7 McMillen KK Schmidt EM Storer BE Bar M Metabolic syndrome appears early after hematopoietic cell transplantation Metab Syndr Relat Disord 2014 12 7 367 371 25006868 10.1089/met.2014.0051
8 Oudin C Auquier P Bertrand Y Contet A Kanold J Sirvent N Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study Bone Marrow Transplant 2015 50 11 1438 1444 26191949 10.1038/bmt.2015.167
9 Grundy SM Cleeman JI Daniels SR Donato KA Eckel RH Franklin BA Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 2005 112 17 2735 2752 16157765 10.1161/CIRCULATIONAHA.105.169404
10 Chow EJ Mueller BA Baker KS Cushing-Haugen KL Flowers ME Martin PJ Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation Ann Intern Med 2011 155 1 21 32 21727290 10.7326/0003-4819-155-1-201107050-00004
11 Oudin C Simeoni MC Sirvent N Contet A Begu-Le Coroller A Bordigoni P Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia Blood 2011 117 17 4442 4448 21278355 10.1182/blood-2010-09-304899
12 Gurney JG Ness KK Sibley SD O'Leary M Dengel DR Lee JM Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia Cancer 2006 107 6 1303 1312 16894525 10.1002/cncr.22120
13 Rizzo JD Wingard JR Tichelli A Lee SJ Van Lint MT Burns LJ Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation Biol Blood Marrow Transplant 2006 12 2 138 151 16443512 10.1016/j.bbmt.2005.09.012
14 Majhail NS Rizzo JD Lee SJ Aljurf M Atsuta Y Bonfim C Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation Biol Blood Marrow Transplant 2012 18 3 348 371 22178693 10.1016/j.bbmt.2011.12.519 PMC3279570
15 Pulsipher MA Skinner R McDonald GB Hingorani S Armenian SH Cooke KR National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines Biol Blood Marrow Transplant 2012 18 3 334 347 22248713 10.1016/j.bbmt.2012.01.003 PMC3281504
16 Isomaa B Almgren P Tuomi T Forsen B Lahti K Nissen M Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 2001 24 4 683 689 11315831 10.2337/diacare.24.4.683
17 Alberti KG Eckel RH Grundy SM Zimmet PZ Cleeman JI Donato KA Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 2009 120 16 1640 1645 19805654 10.1161/CIRCULATIONAHA.109.192644
18 Shin JA Lee JH Lim SY Ha HS Kwon HS Park YM Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness J Diabetes Investig 2013 4 4 334 343 10.1111/jdi.12075 PMC4020225 24843675
19 International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome Available from: http://www.idf.org/metabolic-syndrome
20 Kaur J A comprehensive review on metabolic syndrome Cardiol Res Pract 2014 2014 943162 24711954 10.1155/2014/943162 PMC3966331
21 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001 285 19 2486 2497 11368702 10.1001/jama.285.19.2486
22 Alberti KG Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 1998 15 7 539 553 9686693 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
23 Mancia G Bombelli M Facchetti R Casati A Ronchi I Quarti-Trevano F Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events J Hypertens 2010 28 5 999 1006 20308922 10.1097/HJH.0b013e328337a9e3
24 Lin CC Liu CS Li CI Lin WY Lai MM Lin T The relation of metabolic syndrome according to five definitions to cardiovascular risk factors--a population-based study BMC Public Health 2009 9 484 20028565 10.1186/1471-2458-9-484 PMC2805641
25 Alberti KG Zimmet P Shaw J The metabolic syndrome--a new worldwide definition Lancet 2005 366 9491 1059 1062 16182882 10.1016/S0140-6736(05)67402-8
26 Ogden CL Carroll MD Kit BK Flegal KM Prevalence of childhood and adult obesity in the United States, 2011–2012 JAMA 2014 311 8 806 814 24570244 10.1001/jama.2014.732 PMC4770258
27 World Health Organization Regional Office for Europe - Data and Statistics Available from: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics
28 Jensen MD Ryan DH Apovian CM Ard JD Comuzzie AG Donato KA 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Circulation 2014 129 25 Suppl 2 S102 S138 24222017 10.1161/01.cir.0000437739.71477.ee PMC5819889
29 Despres JP Lemieux I Abdominal obesity and metabolic syndrome Nature 2006 444 7121 881 887 17167477 10.1038/nature05488
30 Amato MC Guarnotta V Giordano C Body composition assessment for the definition of cardiometabolic risk J Endocrinol Invest 2013 36 7 537 543 23612318 10.3275/8943
31 Sorror ML Maris MB Storb R Baron F Sandmaier BM Maloney DG Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 2005 106 8 2912 2919 15994282 10.1182/blood-2005-05-2004 PMC1895304
32 Aplenc R Zhang M-J Sung L Zhu X Ho VT Cooke K Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation Blood 2014 123 22 3504 3511 24711663 10.1182/blood-2013-03-490334 PMC4041168
33 Fuji S Kim S-W Yoshimura K-i Akiyama H Okamoto S-i Sao H Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Biology of Blood and Marrow Transplantation 2009 15 1 73 82 19135945 10.1016/j.bbmt.2008.10.029
34 Fuji S Takano K Mori T Eto T Taniguchi S Ohashi K Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT Bone Marrow Transplant 2014 49 12 1505 1512 25111511 10.1038/bmt.2014.178
35 Baker KS Chow E Steinberger J Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation Bone Marrow Transplant 2012 47 5 619 625 21643022 10.1038/bmt.2011.118 PMC13441451
36 Narici MV Maffulli N Sarcopenia: characteristics, mechanisms and functional significance Br Med Bull 2010 95 139 159 20200012 10.1093/bmb/ldq008
37 Kyle UG Chalandon Y Miralbell R Karsegard VL Hans D Trombetti A Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients Bone Marrow Transplant 2005 35 12 1171 1177 15880127 10.1038/sj.bmt.1704996
38 Li C Liu P Liu L Zhang X Yang P Sheng H Metabolic syndrome in hematologic malignancies survivors: a meta-analysis Medical Oncology 2014 32 1 1 9 10.1007/s12032-014-0422-9 25471791
39 Greenfield DM Boland E Ezaydi Y Ross RJ Ahmedzai SH Snowden JA Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma Bone Marrow Transplant 2014 49 7 907 912 24710566 10.1038/bmt.2014.63
40 Mostoufi-Moab S Ginsberg JP Bunin N Zemel BS Shults J Thayu M Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation J Pediatr 2012 160 1 122 128 21839468 10.1016/j.jpeds.2011.06.041 PMC3218257
41 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002 106 25 3143 3421 12485966
42 Thompson WG Gau GT Hypertriglyceridemia and its pharmacologic treatment among US adults--invited commentary Arch Intern Med 2009 169 6 578 579 19307520 10.1001/archinternmed.2008.594
43 Fodor G Primary prevention of CVD: treating dyslipidaemia BMJ Clin Evid 2008 2008 PMC2907953 19450334
44 Scheidt-Nave C Du Y Knopf H Schienkiewitz A Ziese T Nowossadeck E [Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1)] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013 56 5–6 661 667 23703484 10.1007/s00103-013-1670-0
45 Gonzalez-Juanatey JR Millan J Alegria E Guijarro C Lozano JV Vitale GC [Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study] Rev Esp Cardiol 2011 64 4 286 294 21411216 10.1016/j.recesp.2010.10.030
46 Tichelli A Bucher C Rovo A Stussi G Stern M Paulussen M Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation Blood 2007 110 9 3463 3471 17664354 10.1182/blood-2006-10-054080
47 Kagoya Y Seo S Nannya Y Kurokawa M Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis Clin Transplant 2012 26 2 E168 E175 22507357 10.1111/j.1399-0012.2012.01628.x
48 Blaser BW Kim HT Alyea EP 3rd Ho VT Cutler C Armand P Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2012 18 4 575 583 21839706 10.1016/j.bbmt.2011.08.003 PMC3805283
49 Chow EJ Baker KS Lee SJ Flowers ME Cushing-Haugen KL Inamoto Y Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation J Clin Oncol 2014 32 3 191 198 24297944 10.1200/JCO.2013.52.6582 PMC3887476
50 Griffith ML Savani BN Boord JB Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management Blood 2010 116 8 1197 1204 20439623 10.1182/blood-2010-03-276576
51 Marini BL Choi SW Byersdorfer CA Cronin S Frame DG Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients Biol Blood Marrow Transplant 2015 21 5 809 820 25459644 10.1016/j.bbmt.2014.10.027 PMC4408224
52 Chow EJ Wong K Lee SJ Cushing-Haugen KL Flowers ME Friedman DL Late cardiovascular complications after hematopoietic cell transplantation Biol Blood Marrow Transplant 2014 20 6 794 800 24565992 10.1016/j.bbmt.2014.02.012 PMC4019708
53 Felicetti F D'Ascenzo F Moretti C Corrias A Omede P Marra WG Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry Eur J Prev Cardiol 2015 22 6 762 770 24691151 10.1177/2047487314529348
54 McCrindle BW Urbina EM Dennison BA Jacobson MS Steinberger J Rocchini AP Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing Circulation 2007 115 14 1948 1967 17377073 10.1161/CIRCULATIONAHA.107.181946
55 Kearney PM Whelton M Reynolds K Muntner P Whelton PK He J Global burden of hypertension: analysis of worldwide data Lancet 2005 365 9455 217 223 15652604 10.1016/S0140-6736(05)17741-1
56 James PA Oparil S Carter BL Cushman WC Dennison-Himmelfarb C Handler J 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 2014 311 5 507 520 24352797 10.1001/jama.2013.284427
57 Baker KS Ness KK Steinberger J Carter A Francisco L Burns LJ Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study Blood 2007 109 4 1765 1772 17047152 10.1182/blood-2006-05-022335 PMC1794046
58 Pophali PA Klotz JK Ito S Jain NA Koklanaris E Le RQ Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events Exp Hematol 2014 42 2 83 89 24141092 10.1016/j.exphem.2013.07.003 PMC3929523
59 Majhail NS Challa TR Mulrooney DA Baker KS Burns LJ Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 2009 15 9 1100 1107 19660723 10.1016/j.bbmt.2009.05.010
60 Diagnosis and classification of diabetes mellitus Diabetes Care 2010 33 Suppl 1 S62 S69 20042775 10.2337/dc10-S062 PMC2797383
61 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 1993 329 14 977 986 8366922 10.1056/NEJM199309303291401
62 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 837 853 9742976
63 Schellenberg ES Dryden DM Vandermeer B Ha C Korownyk C Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 2013 159 8 543 551 24126648 10.7326/0003-4819-159-8-201310150-00007
64 Perreault L Pan Q Mather KJ Watson KE Hamman RF Kahn SE Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study Lancet 2012 379 9833 2243 2251 22683134 10.1016/S0140-6736(12)60525-X PMC3555407
65 Selph S Dana T Blazina I Bougatsos C Patel H Chou R Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 2015 162 11 765 776 25867111 10.7326/M14-2221
66 Simmons RK Echouffo-Tcheugui JB Sharp SJ Sargeant LA Williams KM Prevost AT Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial Lancet 2012 380 9855 1741 1748 23040422 10.1016/S0140-6736(12)61422-6 PMC3607818
67 Griffith ML Jagasia M Jagasia SM Diabetes mellitus after hematopoietic stem cell transplantation Endocr Pract 2010 16 4 699 706 20439241 10.4158/EP10027.RA
68 Taskinen M Saarinen-Pihkala UM Hovi L Lipsanen-Nyman M Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood Lancet 2000 356 9234 993 997 11041401 10.1016/S0140-6736(00)02717-3
69 Bizzarri C Pinto RM Ciccone S Brescia LP Locatelli F Cappa M Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation Pediatr Blood Cancer 2015 62 9 1650 1655 26017459 10.1002/pbc.25603
70 Wei C Thyagiarajan MS Hunt LP Shield JP Stevens MC Crowne EC Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell transplantation is associated with lipodystropic and sarcopenic phenotypes Pediatr Blood Cancer 2015 10.1002/pbc.25601 25989749
71 Mostoufi-Moab S Magland J Isaacoff EJ Sun W Rajapakse CS Zemel B Adverse Fat Depots and Marrow Adiposity Are Associated With Skeletal Deficits and Insulin Resistance in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation J Bone Miner Res 2015 10.1002/jbmr.2512 PMC4540662 25801428
72 Hirabayashi K Nakazawa Y Matsuura H Hara Y Kurata T Hirabayashi K Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies Int J Hematol 2014 99 4 477 486 24557711 10.1007/s12185-014-1536-8
73 Chemaitilly W Boulad F Oeffinger KC Sklar CA Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study Bone Marrow Transplant 2009 44 6 339 343 19308039 10.1038/bmt.2009.40
74 Hansson GK Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 2005 352 16 1685 1695 15843671 10.1056/NEJMra043430
75 Stoll G Bendszus M Inflammation and atherosclerosis: novel insights into plaque formation and destabilization Stroke 2006 37 7 1923 1932 16741184 10.1161/01.STR.0000226901.34927.10
76 Lloyd-Jones DM Leip EP Larson MG D'Agostino RB Beiser A Wilson PW Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 2006 113 6 791 798 16461820 10.1161/CIRCULATIONAHA.105.548206
77 Tichelli A Passweg J Wojcik D Rovo A Harousseau JL Masszi T Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation Haematologica 2008 93 8 1203 1210 18556401 10.3324/haematol.12949
78 Armenian SH Sun CL Vase T Ness KK Blum E Francisco L Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease Blood 2012 120 23 4505 4512 23034279 10.1182/blood-2012-06-437178 PMC3512230
79 Chow EJ Simmons JH Roth CL Baker KS Hoffmeister PA Sanders JE Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation Biol Blood Marrow Transplant 2010 16 12 1674 1681 20685399 10.1016/j.bbmt.2010.05.016 PMC2975816
80 Lorini R Cortona L Scaramuzza A De Stefano P Locatelli F Bonetti F Hyperinsulinemia in children and adolescents after bone marrow transplantation Bone Marrow Transplant 1995 15 6 873 877 7581084
81 Rovó A Daikeler T Halter J Heim D Tsakiris DA Stern M Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor Haematologica 2010 96 1 150 155 20851864 10.3324/haematol.2010.030874 PMC3012779
82 Heidenreich PA Trogdon JG Khavjou OA Butler J Dracup K Ezekowitz MD Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association Circulation 2011 123 8 933 944 21262990 10.1161/CIR.0b013e31820a55f5
83 Heron M Deaths: leading causes for 2007 Natl Vital Stat Rep 2011 59 8 1 95 21950210
84 Lozano R Naghavi M Foreman K Lim S Shibuya K Aboyans V Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012 380 9859 2095 2128 23245604 10.1016/S0140-6736(12)61728-0 PMC10790329
85 Krishnamurthi RV Feigin VL Forouzanfar MH Mensah GA Connor M Bennett DA Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 Lancet Glob Health 2013 1 5 e259 e281 25104492 10.1016/S2214-109X(13)70089-5 PMC4181351
86 Lloyd-Jones D Adams R Carnethon M De Simone G Ferguson TB Flegal K Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 2009 119 3 480 486 19171871 10.1161/CIRCULATIONAHA.108.191259
87 Roach ES Golomb MR Adams R Biller J Daniels S Deveber G Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young Stroke 2008 39 9 2644 2691 18635845 10.1161/STROKEAHA.108.189696
88 Riela AR Roach ES Etiology of stroke in children J Child Neurol 1993 8 3 201 220 8409261 10.1177/088307389300800302
89 Sun CL Francisco L Kawashima T Leisenring W Robison LL Baker KS Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study Blood 2010 116 17 3129 3139 quiz 3377 20656930 10.1182/blood-2009-06-229369 PMC2995350
90 Bodas P Rotz S Cerebral vascular abnormalities in pediatric patients with sickle cell disease after hematopoietic cell transplant J Pediatr Hematol Oncol 2014 36 3 190 193 24327127 10.1097/MPH.0000000000000089
91 Walters MC Hardy K Edwards S Adamkiewicz T Barkovich J Bernaudin F Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease Biol Blood Marrow Transplant 2010 16 2 263 272 19822218 10.1016/j.bbmt.2009.10.005 PMC2919571
92 Bhatt VR Balasetti V Jasem JA Giri S Armitage JO Loberiza FR Jr Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation Clin Lymphoma Myeloma Leuk 2015 15 10 606 611 26184063 10.1016/j.clml.2015.06.004
93 Imataki O Uemura M Shintani T Matsumoto K Reversible cerebral vasoconstriction syndrome resulted in cerebral infarction after allogeneic stem cell transplantation: a case report Ann Hematol 2014 93 5 895 896 24061786 10.1007/s00277-013-1891-1
94 Rojas JC Banerjee C Siddiqui F Nourbakhsh B Powell CM Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura Neurology 2013 80 22 e235 e238 23713092 10.1212/WNL.0b013e318294b423 PMC3716404
95 Haghikia A Heeren M Bockmeyer C Haubitz B Gwinner W Progressive multifocal cerebral infarction in a young kidney transplant recipient due to thrombotic microangiopathy BMC Nephrol 2014 15 59 24708483 10.1186/1471-2369-15-59 PMC4234137
96 Meschia JF Bushnell C Boden-Albala B Braun LT Bravata DM Chaturvedi S Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke 2014 45 12 3754 3832 25355838 10.1161/STR.0000000000000046 PMC5020564